ClinicalTrials.gg
RecruitingNCT06454773Updated Jun 12, 2024

To Evaluate the Impact of Consumption of Bioactive Compounds Extracted From Hemp Hull and Black Pepper on Fasting Blood Glucose Levels in People With Pre-diabetes: A Randomized Placebo-Controlled Parallel Arm Trial

A Phase 3 interventional study of NCT/NFT in Intervention, sponsored by Diabetes Foundation, India. Recruiting at 1 site in India. Open to participants aged 25 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-12.

Sponsored by Diabetes Foundation, India · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.
Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
25 Years to 60 Years
Sex
All
01

Study summary

This is randomized controlled parallel arm study on free living Asian Indians. Eligible subjects will undergo one-week run-in period and subjects will be asked to maintain their usual diet and exercise regime. At the end of the run-in period, subjects fulfilling the inclusion/exclusion criteria at this stage will be randomized either to the intervention arm or control arm using computerized random number tables.

The measured parameters will include, 24-h diet recall, food frequency questionnaire, anthropometry including circumferences, height and weight, and blood parameters including blood glucose (fasting), serum insulin (fasting), HbA1c and lipid profile.

Read the detailed description

To study the impact of bioactive compound supplementation on fasting blood glucose.

To study the impact of intervention with bioactive compound on following measures of glycaemia:

  • 24 hr AUC total from CGM Post-prandial glucose regulation
  • iAUC determined from CGM readout up to 2 hr after consumption of a Standard Meal Blood Chemistry
  • Fasting Insulin
  • HbA1c
  • Lipid profile Anthropometry
  • Weight
  • BMI
  • Waist Circumference
02

Conditions studied

  • Intervention
03

In context

Lead sponsor

Diabetes Foundation, India is the lead sponsor of 30 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Prediabetic individuals of range 25-30 kg/m2 and waist circumference ≥80cm for women and ≥90cm for men with Fasting Blood Glucose between 100-125 mg/dL.

Exclusion Criteria:

  • Prediabetic individuals of BMI range 25-30 kg/m2 and waist circumference ≥80cm for women and ≥90cm for men with Fasting Blood Glucose between 100-125 mg/dL.

Exclusion criteria

  1. Weight loss or gain ≥4.5 kg within 90 days of visit 1.
  2. Use of weight loss medications within 90 days of visit 1
  3. History of gastrointestinal surgery (e.g., bariatric surgery) or cosmetic procedures (e.g., liposuction) for weight/fat reducing purposes.
  4. Use of dietary supplements or related products that, in the judgment of the Investigator, are likely to markedly affect weight loss or appetite within 30 days of visit 1.
  5. History of extreme dietary habits (e.g., Atkins diet, etc.), as judged by the Investigator.
  6. History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.
  7. Current medical diagnosis of type 1 or type 2 diabetes mellitus.
  8. ≥48 mmol/mol (6.5%) as measured at visit 1.
  9. History of a chronic gastrointestinal disorder, such as peptic ulcer disease or malabsorption syndrome (mild lactose intolerance or gastroesophageal reflux diseases are acceptable).
  10. Signs or symptoms of an active infection of clinical relevance within 5 days of visit 1. The visit may be rescheduled such that all signs and symptoms have resolved (at the discretion of the Clinical Investigator) at least 5 days prior to visit 1.
  11. Is pregnant, planning to be pregnant during the study period, lactating, or is of and is unwilling to commit to the use of a medically approved form of throughout the study period. The method of contraception must be recorded in the source document.
  12. Any condition the Investigator believes would interfere with his or her ability to provide , comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.
  13. Excessive alcohol consumption (> 2 Drinks, 60 ml of Whisky Per Day).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
130 participants (estimated)

Study arms

  • Active comparator
    intervention

    bioactive compound from black pepper and hemp hull

    Dietary Supplement: NCT/NFT

  • Placebo comparator
    control

    Placebo

    Dietary Supplement: NCT/NFT

Interventions

  • Dietary supplementNCT/NFT

    extract from black pepper and hemp hull

06

What researchers measure

Primary outcomes

  1. fasting blood glucose

    Time frame: 30 days

Secondary outcomes

  1. Body weight

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Dec 2024, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2024
First posted
Jun 12, 2024
StartActual
Jun 1, 2024
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 31, 2024
Last update
Jun 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06454773
Lead sponsor
Diabetes Foundation, India
Collaborators
Brightseed
Responsible party
Dr Anoop Misra (Professor, President, Diabetes Foundation, India) — Principal investigator
First posted
Jun 12, 2024
Start date
Jun 1, 2024
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jun 12, 2024

Study contacts

Anoop Misra
Contact
anoopmisra@gmail.com
49101222

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion